A new approach to peripheral artery disease

A 2025 randomized controlled trial found that GLP-1 receptor agonists, the blockbuster drugs approved to treat diabetes and obesity, boosted the walking ability of people with diabetes and peripheral artery disease (PAD) in the legs. The news is encouraging, since there are few effective treatments for PAD—reduced blood flow in the limbs that leads to pain with activity. However, it will take more evidence before doctors feel comfortable prescribing GLP-1s if a person only has PAD.